AllDocs -> cancers

279 NAT2 GENE POLYMORPHISM IN BLADDER CANCER Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology Vol. 30 (4): 279-288, July - August, 2004 NAT2 GENE POLYMORPHISM IN BLADDER CANCER : A STUDY FROM NORTH INDIA RAMA D. MITTAL, DAYA S.L. SRIVASTAVA, ANIL MANDHANI Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India ABSTRACT Purpose: This study was conducted to examine: 1) whether the NAT2 genotypes are risk factors for bladder cancer , 2) to study possible association of tobacco usage with NAT2 genotype of these patients. Materials and Methods: This case control study was undertaken over a period of 19 months and included 101 bladder cancer patients and 110 controls. The NAT2 genotypes were identified by PCR-RFLP method in peripheral blood DNA samples. ...

Cancer Warning Signs C Change in bowel or bladder habits A A sore that doesn’t heal U Unusual bleeding or discharge T Thickening or lump I Indigestion of difficulty swallowing O Obvious changes in a wart or mole N Nagging cough or hoarseness

192 LAPAROSCOPIC PARTIAL CYSTECTOMY Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology Vol. 30 (3): 192-198, May - June, 2004 LAPAROSCOPIC PARTIAL CYSTECTOMY IN BLADDER CANCER – INITIAL EXPERIENCE MIRANDOLINO B. MARIANO, MARCOS V. TEFILLI Section of Urology, Hospital Mãe de Deus, Porto Alegre, Rio Grande do Sul, Brazil ABSTRACT Proposal: The authors present their initial experience with a selected group of patients who underwent laparoscopic partial cystectomy for treating bladder cancer . Materials and Methods: In the period from June 1997 to April 2000, 6 patients, aged be- tween 38 and 76 years, having transitional cell carcinoma of the bladder , were identified as candidates to partial cystectomy. The procedure employed consisted in laparoscopic partial cystectomy and lym- phadenectomy with exclusive ...

21 Urinary Bladder Cancer Cancer of the urinary bladder is the fifth most common cancer in the United States. Each year, approximately 38,000 men and 15,000 women are diagnosed with bladder cancer . This is the fourth most common type of cancer in men and the eighth most common in women. Like almost any malignancy, bladder cancer is a multifactorial disease with both an environmental and genetic component. The most important known risk factor for bladder cancer is cigarette smoking; cigarette smokers develop bladder cancer two to three times more often than nonsmokers (Silverman et al., in press). Risk increases with amount smoked (number of packs per day), with moderate to heavy smokers experiencing two to five times the risk of nonsmokers. Quitting smoking is associated with a 30% to 60% decrease in risk. Smoking is estimated to be responsible ...

Gene Discovery in Bladder Cancer Progression using cDNA Microarrays Marta Sanchez-Carbayo,* Nicholas D. Socci, † Juan Jose Lozano, ‡ Wentian Li, § Elizabeth Charytonowicz,* Thomas J. Belbin, † Michael B. Prystowsky, † Angel R. Ortiz, ‡ Geoffrey Childs, † and Carlos Cordon-Cardo* From the Division of Molecular Pathology, * Memorial Sloan- Kettering Cancer Center, New York; the Departments of Molecular Genetics and Pathology and the Seaver Center for Bioinformatics, † Albert Einstein College of Medicine, Bronx; the Department of Physiology and Biophysics, ‡ Mt. Sinai School of Medicine, New York; and the Center for Genomics and Human Genetics, § North Shore-Long Island Jewish Research Institute, Manhasset, New ...

Abstract. After the Chernobyl accident in 1986, the incidence of urinary bladder cancers in the Ukraine increased gradually from 26.2 to 43.3 per 100,000 people between 1986 and 2001. In the areas of low level but persistent cesium-137 ( 137 Cs) radio-contamination, a unique atypical radiation-related urinary bladder cystitis named ‘Chernobyl cystitis’, a possible pre- neoplastic condition in humans, has been detected. We have previously documented high incidences of bladder lesions, including severe dysplasias and/or carcinoma in situ , in association with this cystitis and correlating with oxidative DNA damage. To further investigate the molecular mechanisms underlying bladder carcinogenesis with this specific etiology, mutation analysis of p53 gene (exon 5-8) was performed for 11 and 18 paraffin-embedded bladder cancers in Ukrainians, respectively collected ...

Cancer Program information at www.cedars-sinai.edu/ cancer Call 310-423-2440 or 1-800-CEDARS-1 [1-800-233-2771] for information Cancer -specific Support and Information Page 1 of 6 Cancer Program: Cancer -Specific Support and Information Services The following groups provide information and support related to specific types of cancer . Most services are free of charge. • Bladder Cancer American Foundation for Urologic Disease, Inc. 1128 N. Charles St. Baltimore, MD 21201-2463 Telephone: 410-468-1800 Fax: 410-469-1800 • Breast Cancer Encore Plus Sponsored by the YWCA and provides exercise and support programs Telephone: 202-628-3636 Fax: 202-783-7123 In the Los Angeles area: Greater Los Angeles.213-365-2991 Glendale .818-242-4155 Fullerton .714-871-4488 San Pedro..310-547-0831 Reach ...

Bladder Cancer : Underwriting Perspective Underwriting Questions and Answers Bladder cancer is common malignancy of the transitional cells lining the surface of the bladder . There were approximately 56,000 new cases of bladder cancer diagnosed in 2002. There were over 12,000 deaths from bladder cancer in 2002. Bladder cancer is usually diagnosed in person 40 and older, with men being 2-3 times more likely to be affected. The primary risk factor for bladder cancer is smoking. Cigarette smoking has been shown to increase the risk of developing bladder cancer by a factor of five when compared to non-smokers. 50% of men diagnosed with bladder cancer are smokers. 30% of women diagnosed with bladder cancer are smokers. The most common symptom of bladder cancer is blood in the urine, called hematuria. The work up for ...

bladder cancer Electronic Image Safe (Remove for final output) BCG Plus IFN- Combination Therapy Rationale Evidence of synergistic activity Accentuates the TH1 cytokine response Recombinant interferon alfa and BCG have complementary biologic activities Infiltration of lymphocytes and NK cells to bladder (BCG) Increased HLA expression on TCC cells (IFN- ) Increased cytolytic activity of cytotoxic T cells (IFN- ) Recombinant interferon alfa and BCG are biocompatible Reduced dose of BCG may reduce toxicity while maintaining efficacy BCG Plus IFN a Mechanism of Action Bladder Tumor Cell Expressing Activation Markers and BCG Antigens TH1 IL-2 IFN- g TH0 IL-12 TNF- a IL 12 ...

Molecular Mechanisms and Pathways in Bladder Cancer Development and Progression Ichabod Jung, MD, and Edward Messing, MD Background: The basis for bladder cancer development and progression is complex and involves genetic abnormalities. These abnormalities yield phenotypic changes that allow normal transitional cells to become cancerous and finally acquire the “malignant phenotype.” Methods: The authors review the most common genetic alterations in bladder cancer and the molecular mechanisms and pathways involved in the conversion of normal transitional cell into malignant transitional cancer cells. Results: There are several potential genetic changes of the urothelium that eventually cause bladder cancer initiation and tumor progression. Some of these alterations are also found in other malignancies suggesting that key common pathways exist in the ...

Patient Description The patient is a 79-year-old male who presents with significant urinary frequency, urgency, and moderate dysuria of about six months’ duration. He had previously received a two-week course of a fluoroquinolone antibiotic from his primary care physician without clear improvement. He denies fever, chills, flank pain, or gross hematuria. He admits to a moderate decrease in his urinary force of stream, which has remained unchanged over the past year. His medical history is remarkable for two prior diagnoses of myocardial infarction, hypertension, chronic obstructive pulmonary disease, osteoarthritis, and a cerebral vascular accident with minimal motor deficit and mild memory loss. He was treated for tuberculosis 20 years ago. He has no current angina. Medications include atenolol, hydrochlorothiazide, and low-dose ...

bladder cancer Bladder cancer in Antigo, Wisconsin. How to handle a small cluster investigation. Source - Hanrahan LP, Mirkin I, Olson J, Anderson HA, Fiore BJ (1990) SMRFIT: A statistical analysis system (SAS) program for standardized mortality ratio analyses and Poisson regression model fits in community disease cluster investigations. Amer. J. Epid 132;S1:S116-S122. M Basic data required are - M Case counts by age and sex. M Corresponding population figures M Corresponding rates of disease, typically from a registry, or other source of official statistics. M The problem - There was public concern about an apparent excess of bladder cancer ...

bladder cancer Bladder cancer in Antigo, Wisconsin. How to handle a small cluster investigation. Source - Hanrahan LP, Mirkin I, Olson J, Anderson HA, Fiore BJ (1990) SMRFIT: A statistical analysis system (SAS) program for standardized mortality ratio analyses and Poisson regression model fits in community disease cluster investigations. Amer. J. Epid 132;S1:S116-S122. ? Basic data required are - ? Case counts by age and sex. ? Corresponding population figures ? Corresponding rates of disease, typically from a registry, or other source of official statistics. ? The problem - There was public concern about an ...

X. Statistical Tables 96 Oregon State Cancer Registry Average Percent Average Percent Invasive Age Annual Malignant Age Annual Cases Adjusted Trend Deaths Adjusted Trend OREGON COUNTY INCIDENCE MORTALITY Per Year 1 Rate (APC) Per Year Rate (APC) 1996 - 2000 Rates are per 100,000 and age-adjusted to the 2000 U.S. (5-year groups) standard. * Trend is statistically stable. 1 Counts may not match state tables due to cases in unknown counties. ^ Rate not calculated due to instability of small numbers. APC = Average Annual Percent Change DATA Table 3j: Urinary Bladder Cancer State of Oregon 804 23.7 0.0 160 4.7 0.6 Baker ...

TISSUE BIOMARKERS IN CANCER OF THE URINARY BLADDER AND KIDNEY High-throughput tissue microarrays in the study of urinary tract malignancies Harri Visapää Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. Academic Dissertation To be publicly discussed with permission of the Medical Faculty of the University of Helsinki, in auditorium 3 of the Biomedicum Helsinki, Haartmaninkatu 8, on June 7th, 2003, at 12 noon. Helsinki 2003 Page 2 Supervised by Professor Aarno Palotie David Geffen School of Medicine at UCLA, Los Angeles, California, USA, and Finnish Genome Center, University of Helsinki, Helsinki, Finland Reviewed by ...

[ CANCER RESEARCH 62, 6973– 6980, December 1, 2002] Molecular Profiling of Bladder Cancer Using cDNA Microarrays: Defining Histogenesis and Biological Phenotypes 1 Marta Sanchez-Carbayo, 2 Nicholas D. Socci, Elizabeth Charytonowicz, Minglan Lu, Michael Prystowsky, Geoffrey Childs, and Carlos Cordon-Cardo Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [M. S-C., E. C., M. L., C. C-C.], and Department of Pathology, Seaver Foundation for Bioinformatics [N. D. S.] and Department of Molecular Genetics [M. P., C. C-C.], Albert Einstein College of Medicine, Bronx, New York 10461 ABSTRACT This study was designed to characterize the expression profiles of nine bladder cancer cell lines (T24, J82, 5637, HT1376, RT4, SCaBER, TCCSUP, UMUC-3, and HT1197) using cDNA microarrays (8976 genes ...

bladder cancer Surgical Management of Bladder Cancer Colin Bunce Urologist Barnet and Chase Farm Hospitals 28 February 2003 Epidemiology About 12,000 new cases per annum Male to female ratio about 3:1 Risk factors – smoking and chemicals Disease of late middle age and elderly Long “latency period” from exposure to disease Increased rates in patients after pelvic radiotherapy for other disease Pathology 90% are TCC About 5% adenocarcinoma (extrophy) About 5% squammous carcinoma (chronic irritation) 70% “superficial” at presentation Mortality rate of about 23% for all grades and stages and rising Diagnosis (1) ...

All-Ireland cancer statistics 1994-96 89 Bladder 20. MALIGNANT CANCER OF THE BLADDER (summary) ICD-O.2 C67 ICD-10 C67 ICD-9 188 Key facts • At least 705 cases per year, 1994-96: 210 in females, 495 in males. • Average of 265 deaths per year: 87 in females, 178 in males. • Age-standardised incidence and mortality rates about three times higher in males than females. • 5th most common site for cancer incidence in males, 12th (or higher) in females. • 8th most common cause of cancer deaths in males, 11th in females. • Irish incidence rates above EU average for females, at least, but international comparisons are complicated by lack of consistency in how "malignant" tumours of the bladder are defined. Summary statistics Table 20.1 Incidence 1994-96 On average each year, at ...

abstracted & translated by Honora Lee Wolfe , Dipl. Ac., Lic. Ac., FNAAOM K e y w o r d s : Chinese medicine, acupuncture, warm needle, post cervical cancer radical sur- gery bladder numbness Radical hysterectomy for cervical cancer can damage the nerves associated with the bladder . Therefore, there can be post-operative bladder numbness and urinary retention. Xie Ying pub- lished an article titled, “A Clinical Audit of the Treatment of 136 Cases of Post Cervical Cancer Radical Surgery Bladder Numbness with Warm Needle Moxibustion,” in issue #4, 2002 of Zhong Yi Za Zhi (Journal of Chinese Medicine) on page 267. A precis of this article appears below. Cohort description: One hundred thirty-six women with post-opera- tive cervical cancer bladder numbness were divided into three groups. The treatment group ...

CME Posttest FAQs on Intravesical Immunotherapy for Superficial Bladder Cancer Release Date: July 15, 2002 CME Instructions This activity comprises four parts to be sent to you throughout the year. To earn credit, you must read and complete all four parts. To receive documentation of your participation in this four-part CME activity for a total of 1 hour of CME credit, please complete the following steps: 1. Read each newsletter. 2. Complete the CME posttest included in each of the four parts. 3. Mail or fax each of the completed posttests to Projects In Knowledge SM , One Harmon Plaza, Secaucus, NJ 07094; fax: 1-201-617-7333. 4. After reading the final part, complete the CME evaluation survey contained therein. 5. Mail or fax your final posttest and the CME evaluation survey to Projects In Knowledge at the address and fax number above. At the end of the series, Projects ...

bladder cancer HrQoL after Radical Cystectomy and Urinary Diversion for Bladder Cancer : A Systematic Review of the Literature Michael Porter HSERV 584 3.10.2004 Bladder Cancer 5th most common malignancy in the U.S. In 2003 57,400 incident cases 12,500 deaths For invasive bladder cancer , the only proven curative procedure is radical cystectomy (removal of the bladder ) Conduit diversion Continent reservoir Neobladder Urinary Diversion after Cystectomy All diversions offer similar disease specific outcomes (e.g. cancer control, survival) Neobladder has evolved into the “gold standard” for diversion More difficult, larger operation Perceived QOL benefits after recovery Concise summation of QOL literature has never been performed ...

bladder cancer HrQoL After Urinary Diversion for Invasive Bladder Cancer Michael Porter HSERV 584 Bladder Cancer 55,000 cases and 12,500 deaths annually in U.S. Definitive treatment for invasive bladder cancer is radical cystectomy Urinary tract needs to be reconstructed with bowel after bladder removal 3 main options ? conduit, continent reservoir, neobladder HrQoL Widely assumed to be better for continent and orthotopic diversions No systematic review of the literature exists, and the current state of QOL research after radical cystectomy is unclear Systematic review Medline search 1966-present (January 28, 2004)-combined following search results neobladder + quality of life continent reservoir + quality of life ileal conduit + quality of life urinary diversion + quality ...

COMMENTS ON LOCAL COVERAGE DETERMINATION ON IMMUNOASSAY FOR BLADDER CANCER Comment: Comments submitted from the manufacturer of the NMP22 test noted that the FDA approval for the BTA and NMP22 tests differ in that only the latter is approved for the diagnosis of bladder cancer when used in conjunction with cystoscopy, and that the BTA test is only approved for monitoring. They have requested that the policy distinguish between the uses of these tests. Response: The draft policy section “LMRP Abstract” already indicates that both tests are approved for monitoring, and that only the NMP22 test is approved as an adjunctive test for diagnosis. However, do to reformatting of Local Coverage Decisions, this information may be lost. Therefore we will amend the indications section to state that only tests FDA-approved for diagnosis may be used for diagnosis in addition to monitoring. Comment: ...

Dr Willem Oosterlinck is currently Chairman of the Superficial Bladder Cancer Committee of the European Organisation for Research and Treatment of Cancer (EORTC) and heads the Department of Urology at the University Hospital Ghent in Belgium. Formerly President of the Belgian Society of Urology (BVU) and the Belgian Congress of Urology, he is currently a member of the Accreditation Commission for Urology of the Ministry of Health, the European Urological Association (EAU), The Société Internationale d’Urologie (SIU) and BVU. Dr Oosterlinck was also Chairman of the committee responsible for development of guidelines on superficial bladder tumours in the EAU. He began his career at the University Hospital Ghent as a Senior Assistant in Urology and advanced to Adjunct Director of the Department of Urology, prior to earning his current position. ...

Bladder Cancer Page 2 Bladder Cancer Bladder cancer is a common cancer of the urinary tract. This pamphlet will give you answers to some commonly asked questions about bladder cancer . It will explain how it is diagnosed and treated. What is the bladder ? The bladder is a muscular sac that stores urine. In females, it is behind the pubic bone and in front of the vagina and uterus. In males, the bladder sits behind the pubic bone and in front of the bowel. Kidney Ureter Bladder Page 3 Who is at risk to get bladder cancer ? Three out of 4 people with bladder cancer are men. Most are between the ages of 45 and 80. Smoking may cause bladder cancer . Certain dyes and chemicals compounds may also increase the risk of bladder ...